2014 Press Releases
|03/13/14||GenVec Announces $9 Million Registered Direct Offering|
|GAITHERSBURG, Md., March 13, 2014 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) ("GenVec") today announced it has agreed to sell approximately $9 million of shares of its common stock to selected institutional investors in a registered direct offering at a price of $3.15 per share. In the offering, GenVec will issue approximately 2,870,000 shares of its common stock. The closing of the offering is expected to take place on or about March 18, 2014, subject to the satisfaction of customary closing c... |
|03/03/14||GenVec to Present at 26th Annual ROTH Conference|
|GAITHERSBURG, Md., March 3, 2014 /PRNewswire/ -- GenVec, Inc. (NASDAQ:GNVC) announced today that the Company will participate in the 26th Annual ROTH Conference being held March 9-12, 2014 in Dana Point, California. Douglas Swirsky, President and CEO of GenVec, will present a company overview on Monday, March 10, 2014 at 3:00 pm Pacific Daylight Time.
A webcast of Mr. Swirsky's presentation will be available both live and on replay. The presentation will be available via webcast at http://wsw... |
|02/13/14||GenVec Achieves Third Milestone In Hearing And Balance Collaboration|
|GAITHERSBURG, Md., Feb. 13, 2014 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today announced that the company has achieved the third milestone in its collaboration with Novartis for the development of treatments for hearing and balance disorders. In January 2014, Novartis filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) for the clinical development of CGF166, the lead product candidate under the collaboration. The IND was deemed effective on Febru... |
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.